Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $5.84 USD
Change Today -0.16 / -2.67%
Volume 1.7M
INO On Other Exchanges
As of 8:10 PM 02/9/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

660 West Germantown Pike

Suite 100

Plymouth Meeting, PA 19462

United States

Phone: 267-440-4200

Fax: 267-440-4242

Inovio Pharmaceuticals, Inc. engages in developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company’s DNA-based immunotherapies, in combination with its proprietary electroporation delivery devices, are intended to generate immune responses, in particular T cells, to fight such diseases. Its novel SynCon immunotherapy design has shown the ability to help break the immune system’s tolerance of cancerous cells. Alternatively, the company’s SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza, and Ebola. The company’s partners and collaborators include F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases (NIAID), United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, HIV Vaccines Trial Network (HVTN), Defense Advanced Research Projects Agency, and MedImmune, LLC. Products and Product Development The company’s primary focus is to independently and/or in partnerships advance the products developed from its integrated platform consisting of its SynCon immunotherapy and CELLECTRA electroporation technologies. The company is developing various DNA-based immunotherapies for the prevention or treatment of cancer and chronic infectious diseases. Cancer Vaccines/Immunotherapies HPV Immunotherapy-VGX-3100 Late Stage Cervical Dysplasia (CIN 2/3) The company’s VGX-3100 is an immunotherapy designed to increase immune responses (humoral and cell mediated) against the E6 and E7 antigens of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. The company completed a phase I study of its cervical dysplasia immunotherapy (VGX-3100) in 2010. This dose escalation study tested the safety and immunogenicity of VGX-3100 in women previously treated for moderate or severe cervical intraepithelial neoplasia (CIN 2/3), a high grade premalignant lesion that is a precursor of cervical cancer. In 2014, the company released top line efficacy data from this phase II clinical trial (HPV-003) for VGX-3100. Based on the preliminary phase II results, the company has stated its intention to advance VGX-3100 into a phase III study in early 2016. The company intends to obtain alignment with the FDA and various global regulatory agencies on the details of the pivotal phase III program to support an indication in CIN2/3. The company has conducted additional market research with physicians and patients that have further characterized the unmet medical needs relating to the treatment of high grade cervical dysplasia (CIN 2/3). HPV Immunotherapy-INO-3112 (VGX-3100 +DNA-Based IL-12 Cytokine INO-9012) Head and Neck Cancer and Cervical Cancer In 2014, the company initiated a phase I/IIa clinical study assessing the immunogenicity and safety of INO-3112 (VGX-3100 in combination with a DNA-based IL-12 cytokine (INO-9012)) in head and neck cancer patients. In 2014, the company also initiated a phase I/IIa clinical study assessing the immunogenicity and safety of INO-3112 (VGX-3100 in combination with INO-9112) in cervical cancer patients. HPV Immunotherapy-INO-3106 +/- DNA-Based IL-12 Cytokine Aerodigestive Cancer Further expanding the company’s HPV portfolio, it launched a compassionate phase I clinical trial in patients with HPV-caused aerodigestive cancer. The company plans to initiate a phase I clinical trial for INO-5150 in the first half of 2015. hTERT (Human Telomerase Reverse Transcriptase) Immunotherapy-INO-1400 In 2013, the company announced that its hTERT DNA cancer immunotherapy administered


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $5.84 USD -0.16

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $13.15 USD +0.51
Novavax Inc $4.62 USD -0.03
Peregrine Pharmaceuticals Inc $0.88 USD +0.0013
Transgene SA €2.80 EUR -0.28
Vical Inc $0.34 USD +0.0078
View Industry Companies

Industry Analysis


Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.7x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact INOVIO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at